---
title: "Cetuximab"
slug: "cetuximab"
date: "2023-09-15"
enableToc: false
tags:
  - building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[regimens of treatment of metastatic colorectal cancer]]

# Cetuximab

ç´„3%çš„ â†’ ç—…æ‚£ä¸­å ±å‘Šæœ‰åš´é‡çš„ â†’ è¼¸æ¶²ç›¸é—œæ•ˆæ‡‰ (ç½•è¦‹è‡´å‘½)

- è‹¥ç™¼ç”Ÿåš´é‡è¼¸æ¶²ç›¸é—œæ•ˆæ‡‰ï¼Œå¿…é ˆç«‹å³ä¸”æ°¸ä¹…åœ°åœæ­¢ä½¿ç”¨cetuximab
- æ­¤å¤–ï¼Œæ¥å—å«æœ‰cetuximabçš„ â†’ è¼»å°„ç™‚æ³•ä¸”æ‚£æœ‰é ­é ¸éƒ¨é±—ç‹€ç´°èƒç™Œçš„ â†’ ç—…æ‚£ä¸­æœ‰2%å ±å‘Šå¿ƒè‚ºåœæ­¢å’Œ/æˆ–çªç„¶æ­»äº¡
- åœ¨cetuximabæ²»ç™‚æœŸé–“åŠä¹‹å¾Œå¿…é ˆå¯†åˆ‡ç›£æ§è¡€æ¸…é›»è§£è³ª (åŒ…æ‹¬ â‰¡ é‚ï¼Œé‰€ï¼Œå’Œéˆ£) ã€‚

- Initial cetuximab dose of 400 mg/m2, followed by 250 mg/m2 once weekly until disease progression or unacceptable toxicity occurs.
  - Colorectal cancer, metastatic, KRAS-wild type, EGFR expressing: Cetuximab single agent therapy or in combination with irinotecan or FOLFIRI (irinotecan, fluorouracil, and leucovorin): Note: When given in combination with irinotecan or FOLFIRI, complete cetuximab dose 1 hour prior to chemotherapy.
  - Weekly dosing:
  - Initial loading dose: IV: 400 mg/m2 infused over 120 minutes.
  - Maintenance dose: IV: 250 mg/m2 infused over 60 minutes once weekly until disease progression or unacceptable toxicity.
  - Biweekly dosing:
    - Initial and subsequent doses: IV: 500 mg/m2 infused over 120 minutes once every 2 weeks until disease progression or unacceptable toxicity.
  - Acneiform eruption (87%), changes in nails (31%), desquamation (â‰¤95%), pruritus (16% to 47%), radiodermatitis (86%), skin rash (â‰¤95%), xeroderma (57%)
  - Endocrine & metabolic: Dehydration (13% to 25%), hypomagnesemia (55%), wt loss (84%)
  - 

[[cetuximab vs panitumumab]]
